Literature DB >> 12920633

Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome.

Gabriela C Fernández1, Maroeska W M Te Loo, Thea J A van der Velden, Lambert P W van der Heuvel, Marina S Palermo, Leo L A Monnens.   

Abstract

The typical form of hemolytic uremic syndrome (D+HUS) is a thrombotic microangiopathy that causes acute renal failure in children. The etiology of this disease is a toxin called Shiga-like toxin (Stx), present in certain strains of gram-negative bacteria. Vascular endothelial cell (EC) injury appears to be central in the pathogenesis of D+HUS. Thrombomodulin (TM) is a glycoprotein present in EC with anti-thrombogenic properties. The objective of this study was to investigate the effects of Stx on the surface expression of TM in EC using an in vitro culture of human glomerular microvascular endothelial cells. We also evaluated other inflammatory mediators [tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide], which are known to increase Stx receptor expression and are potentially involved in the pathogenesis of D+HUS. Stx2 induced a significant decrease of TM expression in this cell type after pre-incubation with TNF-alpha. This decrease could not be attributed to the inhibition of protein synthesis only, as cycloheximide, another inhibitor of protein synthesis, did not affect TM surface expression. These results suggest that the Stx2-induced decrease of TM expression in glomerular EC might contribute to the local procoagulant state present in D+HUS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920633     DOI: 10.1007/s00467-003-1236-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome.

Authors:  C H Nevard; A D Blann; K M Jurd; G B Haycock; B J Hunt
Journal:  Pediatr Nephrol       Date:  1999-08       Impact factor: 3.714

2.  Plasma thrombomodulin in health and diseases.

Authors:  S Takano; S Kimura; S Ohdama; N Aoki
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

3.  Plasma thrombomodulin concentrations in uraemic children.

Authors:  S Ozdemir; N Beşbaş; U Saatçi; A Bakkaloğlu
Journal:  Nephrol Dial Transplant       Date:  1996-11       Impact factor: 5.992

4.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 5.  The hemolytic uremic syndrome.

Authors:  G Remuzzi; P Ruggenenti
Journal:  Kidney Int       Date:  1995-07       Impact factor: 10.612

6.  Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells.

Authors:  P A van Setten; V W van Hinsbergh; T J van der Velden; N C van de Kar; M Vermeer; J D Mahan; K J Assmann; L P van den Heuvel; L A Monnens
Journal:  Kidney Int       Date:  1997-04       Impact factor: 10.612

7.  Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.

Authors:  William D Campbell; Eliada Lazoura; Noriko Okada; Hidechika Okada
Journal:  Microbiol Immunol       Date:  2002       Impact factor: 1.955

8.  Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: differential responses in keratinocytes and endothelial cells.

Authors:  T J Raife; E M Demetroulis; S R Lentz
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

9.  A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.

Authors:  Y Harel; M Silva; B Giroir; A Weinberg; T B Cleary; B Beutler
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Quantification and modulation of thrombomodulin activity in isolated rat and human glomeruli.

Authors:  C J He; A Kanfer
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

View more
  12 in total

1.  Decrease of thrombomodulin contributes to the procoagulant state of endothelium in haemolytic uraemic syndrome.

Authors:  Julie M Williams; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2005-02       Impact factor: 3.714

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Authors:  Leticia H Nolasco; Nancy A Turner; Aubrey Bernardo; Zhenyin Tao; Thomas G Cleary; Jing-Fei Dong; Joel L Moake
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

4.  Compensatory renal growth protects mice against Shiga toxin 2-induced toxicity.

Authors:  Gabriela Verónica Camerano; Oscar David Bustuoabad; Roberto Pablo Meiss; Sonia Alejandra Gómez; Gabriela Cristina Fernández; Martín Amadeo Isturiz; Marina Sandra Palermo; Graciela Isabel Dran
Journal:  Pediatr Nephrol       Date:  2006-05-16       Impact factor: 3.714

Review 5.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

Review 6.  The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications.

Authors:  Silvio Danese; Stefania Vetrano; Li Zhang; Victoria A Poplis; Francis J Castellino
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

7.  Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Authors:  Friedrich Modde; Putri Andina Agustian; Juliane Wittig; Maximilian Ernst Dämmrich; Vinzent Forstmeier; Udo Vester; Thurid Ahlenstiel; Kerstin Froede; Ulrich Budde; Anne-Margret Wingen; Anke Schwarz; Svjetlana Lovric; Jan Thomas Kielstein; Carsten Bergmann; Nadine Bachmann; Mato Nagel; Hans Heinrich Kreipe; Verena Bröcker; Clemens Luitpold Bockmeyer; Jan Ulrich Becker
Journal:  Virchows Arch       Date:  2013-03-09       Impact factor: 4.064

Review 8.  Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.

Authors:  Lindsay S Keir; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2013-07-11       Impact factor: 3.714

Review 9.  Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.

Authors:  Chad L Mayer; Caitlin S Leibowitz; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2012-11-08       Impact factor: 4.546

Review 10.  Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Authors:  Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.